IRADIMED Corporation — FY2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. The filing is an annual report, not a standalone fourth-quarter filing; selected unaudited Q4 results are included below.
Business context
IRADIMED develops and sells MRI-compatible infusion pumps, patient vital-sign monitors, accessories, disposable IV tubing and related services, primarily to hospitals and acute-care facilities. Its established business is heavily dependent on the MRidium infusion pump. The company began limited international shipments of its new 3880 monitor in December 2016; U.S. sales awaited FDA clearance.
Key financial metrics
| Metric | FY2016 | FY2015 |
|---|---|---|
| Revenue | $32.5 million | $31.6 million |
| Gross profit / margin | $26.3 million / 81.1% | $25.8 million / 81.5% |
| Operating income / margin | $10.9 million / 33.6% | $11.5 million / 36.4% |
| Net income | $7.2 million | $7.5 million |
| Diluted EPS | $0.60 | $0.60 |
| Cash from operations | $9.4 million | $7.6 million |
| Cash and cash equivalents | $17.7 million | $19.4 million |
| Investments | $8.0 million | $7.6 million |
| Working capital | $30.5 million | $31.1 million |
| Total liabilities | $5.3 million | $3.3 million |
The company reported no officer note payable at year-end and disclosed no off-balance-sheet arrangements. Operating cash flow was positive; financing cash use of $9.1 million primarily reflected approximately $10.0 million of share repurchases.
Q4 2016: Revenue was $6.0 million versus $8.8 million in Q4 2015; operating income was $1.5 million versus $3.4 million; net income was $1.1 million versus $2.4 million. The filing does not provide quarterly cash-flow figures.
Changes versus prior period
- Full-year revenue rose 2.9%, while net income fell about 4.2% and operating income fell about 5.2%.
- U.S. revenue was essentially flat at $28.9 million; international revenue increased 31.2% to $3.6 million.
- Infusion-pump system revenue declined 2.5% to $25.7 million; disposable IV sets and services grew 28.1% to $6.7 million. Pump systems recognized as revenue fell to 837 from 956, while average selling price rose to approximately $30,500 from $27,500.
- Gross margin eased 0.4 percentage point. Management cited lower production output and unfavorable inventory adjustments, partly offset by sales mix.
- Operating expenses increased 8.3%, chiefly from higher general and administrative and sales and marketing costs. R&D expense declined, in part because $0.7 million of monitor software development costs was capitalized.
- Cash and investments together declined to $25.7 million from $27.0 million; inventory increased to $3.9 million from $2.4 million.
Outlook, risks and unusual items
- Management expected 2017 revenue to decrease as sales moved beyond prior growth from converting customers away from a discontinued competitor pump and focused on first-time adopters and broader hospital use. No numerical revenue guidance was provided.
- Management expected operating expenses to decrease marginally in 2017, with lower regulatory and R&D costs partly offset by hiring, monitor launch costs and higher depreciation and amortization.
- The company expected U.S. shipments of the 3880 monitor in the second half of 2017, subject to FDA clearance; it anticipated international monitor sales to expand during 2017.
- The FDA cleared the MRidium 3860+ pump, including DERS, on December 15, 2016. The FDA Warning Letter nevertheless remained open at year-end. Following its July 2016 inspection, the FDA stated no further actions were necessary in response to the Warning Letter findings. A field software update for existing pumps was underway after year-end, with completion expected in the first half of 2017; related expenses were accrued and expected to be not significant.
- Key risks include dependence on one principal product, regulatory action or delays, competition in MRI monitors, extended sales cycles, single-source components and reliance on one Florida manufacturing facility. The MRI pump’s ultrasonic motor is single-sourced; the supply agreement runs through 2019.
- The company repurchased 569,213 shares for approximately $10.0 million during 2016. It stated that it did not expect to pay cash dividends in the foreseeable future.
- Other items to note: medical-device excise tax was suspended for 2016 and 2017; a related-party lease with the CEO’s affiliate covers the headquarters and manufacturing facility; and the filing reports no current legal proceeding expected to materially affect results.
Most important facts for investors to verify
- Progress toward closing the FDA Warning Letter and completion of the MRidium software field update.
- FDA clearance and timing of U.S. commercialization for the 3880 monitor, plus evidence of customer adoption and sales.
- Whether the anticipated 2017 revenue decline occurred and how pump-unit volumes, pricing and recurring disposable/service revenue developed.
- Inventory growth, cash generation and the effect of capital spending, share repurchases and stock-based compensation on liquidity and per-share results.
- Continuity and pricing terms for the sole-source pump motor and other critical components.